On Feb 04, 2026, NVO reported earnings of 6.32 USD per share (EPS) for Q4 25, beating the estimate of 5.97 USD, resulting in a 5.77% surprise. Revenue reached 77.99 billion, compared to an expected 78.44 billion, with a -0.58% difference. The market reacted with a -6.18% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 4 analysts forecast an EPS of 6.00 USD, with revenue projected to reach 120.76 billion USD, implying an decrease of -5.06% EPS, and increase of 54.83% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Eli Lilly & Co.
Report Date
Feb 04, 2026 For Q4 25
Estimate
$6.73
Actual
$7.54
Surprise
+11.92%
ABBVIE INC.
Report Date
Feb 04, 2026 For Q4 25
Estimate
$2.70
Actual
$2.71
Surprise
+0.17%
Novartis AG
Report Date
Feb 04, 2026 For Q4 25
Estimate
$2.02
Actual
$2.02
Surprise
+0.27%
Merck & Co., Inc.
Report Date
Feb 03, 2026 For Q4 25
Estimate
$2.02
Actual
$2.04
Surprise
+0.52%
Pfizer Inc.
Report Date
Feb 03, 2026 For Q4 25
Estimate
$0.57
Actual
$0.66
Surprise
+14.29%
Sanofi - ADR
Report Date
Jan 29, 2026 For Q4 25
Estimate
$1.46
Actual
$1.53
Surprise
+4.22%
FAQ
What were Novo-Nordisk A/S's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Novo-Nordisk A/S reported EPS of $6.32, beating estimates by 5.77%, and revenue of $77.99B, -0.58% below expectations.
How did the market react to Novo-Nordisk A/S's Q4 2025 earnings?
The stock price moved down -6.18%, changed from $50.30 before the earnings release to $47.19 the day after.
When is Novo-Nordisk A/S expected to report next?
The next earning report is scheduled for May 05, 2026.
What are the forecasts for Novo-Nordisk A/S's next earnings report?
Based on 4
analysts, Novo-Nordisk A/S is expected to report EPS of $6.00 and revenue of $120.76B for Q1 2026.